|
1
|
Biesenbach G: Highest mortality during the
last year before and the first year after start of dialysis
treatment in type 2 diabetic patients with nephropathy. Curr
Diabetes Rev. 3:123–126. 2007. View Article : Google Scholar
|
|
2
|
Schernthaner G: Kidney disease in
diabetology: Lessons from 2007. Nephrol Dial Transplant.
23:1112–1115. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Simonson MS: Phenotypic transitions and
fibrosis in diabetic nephropathy. Kidney Int. 71:846–854. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qian Y, Feldman E, Pennathur S, Kretzler M
and Brosius FC III: From fibrosis to sclerosis: Mechanisms of
glomerulosclerosis in diabetic nephropathy. Diabetes. 57:1439–1445.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Swaminathan S and Shah SV: Novel
approaches targeted toward oxidative stress for the treatment of
chronic kidney disease. Curr Opin Nephrol Hypertens. 17:143–148.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohga S, Shikata K, Yozai K, Okada S, Ogawa
D, Usui H, Wada J, Shikata Y and Makino H: Thiazolidinedione
ameliorates renal injury in experimental diabetic rats through
anti-inflammatory effects mediated by inhibition of NF-kappaB
activation. Am J Physiol Renal Physiol. 292:F1141–1150. 2007.
View Article : Google Scholar
|
|
7
|
Willson TM, Lambert MH and Kliewer SA:
Peroxisome proliferator-activated receptor gamma and metabolic
disease. Annu Rev Biochem. 70:341–367. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baylis C, Atzpodien EA, Freshr G and
Engels K: Peroxisome proliferator-activated receptor [gamma]
agonist provides superior renal protection versus
angiotensin-converting enzyme inhibition in a rat model of type 2
diabetes with obesity. J Pharmacol Exp Ther. 307:854–860. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Zhang D, Li J, Zhang X, Fan F and
Guan Y: Role of PPARgamma in renoprotection in Type 2 diabetes:
Molecular mechanisms and therapeutic potential. Clin Sci (Lond).
116:17–26. 2009. View Article : Google Scholar
|
|
10
|
Yang J, Zhou Y and Guan Y: PPARgamma as a
therapeutic target in diabetic nephropathy and other renal
diseases. Curr Opin Nephrol Hypertens. 21:97–105. 2012. View Article : Google Scholar
|
|
11
|
Hu W, Yu Q, Zhang J and Liu D:
Rosiglitazone ameliorates diabetic nephropathy by reducing the
expression of Chemerin and ChemR23 in the kidney of
streptozotocin-induced diabetic rats. Inflammation. 35:1287–1293.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arora MK, Reddy K and Balakumar P: The low
dose combination of fenofibrate and rosiglitazone halts the
progression of diabetes-induced experimental nephropathy. Eur J
Pharmacol. 636:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Groop PH, Thomas MC, Moran JL, Wadèn J,
Thorn LM, Mäkinen VP, Rosengård-Bärlund M, Saraheimo M, Hietala K,
Heikkilä O, et al: The presence and severity of chronic kidney
disease predicts all-cause mortality in type 1 diabetes. Diabetes.
58:1651–1658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fogo AB: PPARgamma and chronic kidney
disease. Pediatr Nephrol. 26:347–351. 2011. View Article : Google Scholar
|
|
15
|
Iglesias P and Díez JJ: Peroxisome
proliferator-activated receptor gamma agonists in renal disease.
Eur J Endocrinol. 154:613–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elmarakby AA and Sullivan JC: Relationship
between oxidative stress and inflammatory cytokines in diabetic
nephropathy. Cardiovasc Ther. 30:49–59. 2012. View Article : Google Scholar
|
|
17
|
Gumieniczek A: Effect of the new
thiazolidinedione-pioglitazone on the development of oxidative
stress in liver and kidney of diabetic rabbits. Life Sci.
74:553–562. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lakshmanan AP, Watanabe K, Thandavarayan
RA, Sari FR, Harima M, Giridharan VV, Soetikno V, Kodama M and
Aizawa Y: Telmisartan attenuates oxidative stress and renal
fibrosis in streptozotocin induced diabetic mice with the
alteration of angiotensin-(1–7) mas receptor expression associated
with its PPAR-gamma agonist action. Free Radic Res. 45:575–584.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsui T, Yamagishi S, Ueda S, Nakamura K,
Imaizumi T, Takeuchi M and Inoue H: Telmisartan, an angiotensin II
type 1 receptor blocker, inhibits advanced glycation end-product
(AGE)-induced monocyte chemoattractant protein-1 expression in
mesangial cells through downregulation of receptor for AGEs via
peroxisome proliferator-activated receptor-gamma activation. J Int
Med Res. 35:482–489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matsui T, Yamagishi S, Takeuchi M, Ueda S,
Fukami K and Okuda S: Nifedipine inhibits advanced glycation end
products (AGEs) and their receptor (RAGE) interaction-mediated
proximal tubular cell injury via peroxisome proliferator-activated
receptor-gamma activation. Biochem Biophys Res Commun. 398:326–330.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohamed R, Jayakumar C, Ranganathan PV,
Ganapathy V and Ramesh G: Kidney proximal tubular
epithelial-specific overexpression of netrin-1 suppresses
inflammation and albuminuria through suppression of COX-2-mediated
PGE2 production in streptozotocin-induced diabetic mice. Am J
Pathol. 181:1991–2002. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jaradat MS, Wongsud B, Phornchirasilp S,
Rangwala SM, Shams G, Sutton M, Romstedt KJ, Noonan DJ and Feller
DR: Activation of peroxisome proliferator-activated receptor
isoforms and inhibition of prostaglandin H(2) synthases by
ibuprofen, naproxen and indomethacin. Biochem Pharmacol.
62:1587–1595. 2001. View Article : Google Scholar
|
|
23
|
Couto M: Laboratory guidelines for animal
care. Methods Mol Biol. 770:579–599. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haidara MA, Mikhailidis DP, Rateb MA,
Ahmed ZA, Yassin HZ, Ibrahim IM and Rashed LA: Evaluation of the
effect of oxidative stress and vitamin E supplementation on renal
function in rats with streptozotocin-induced Type 1 diabetes. J
Diabetes Complications. 23:130–136. 2009. View Article : Google Scholar
|
|
25
|
Wybenga DR, Di Giorgio J and Pileggi VJ:
Manual and automated methods for urea nitrogen measurement in whole
serum. Clin Chem. 17:891–895. 1971.PubMed/NCBI
|
|
26
|
Liu YW, Zhu X, Zhang L, Lu Q, Wang JY,
Zhang F, Guo H, Yin JL and Yin XX: Up-regulation of glyoxalase 1 by
mangiferin prevents diabetic nephropathy progression in
streptozotocin-induced diabetic rats. Eur J Pharmacol. 721:355–364.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu YW, Zhu X, Yang QQ, Lu Q, Wang JY, Li
HP, Wei YQ, Yin JL and Yin XX: Suppression of methylglyoxal
hyperactivity by mangiferin can prevent diabetes-associated
cognitive decline in rats. Psychopharmacology (Berl). 228:585–594.
2013. View Article : Google Scholar
|
|
28
|
Chow FY, Nikolic-Paterson DJ, Atkins RC
and Tesch GH: Macrophages in streptozotocin-induced diabetic
nephropathy: Potential role in renal fibrosis. Nephrol Dial
Transplant. 19:2987–2996. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nguyen D, Ping F, Mu W, Hill P, Atkins RC
and Chadban SJ: Macrophage accumulation in human progressive
diabetic nephropathy. Nephrology (Carlton). 11:226–231. 2006.
View Article : Google Scholar
|
|
30
|
Rivero A, Mora C, Muros M, García J,
Herrera H and Navarro-González JF: Pathogenic perspectives for the
role of inflammation in diabetic nephropathy. Clin Sci (Lond).
116:479–492. 2009. View Article : Google Scholar
|
|
31
|
Tuttle KR: Linking metabolism and
immunology: Diabetic nephropathy is an inflammatory disease. J Am
Soc Nephrol. 16:1537–1538. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yozai K, Shikata K, Sasaki M, Tone A, Ohga
S, Usui H, Okada S, Wada J, Nagase R, Ogawa D, et al: Methotrexate
prevents renal injury in experimental diabetic rats via
anti-inflammatory actions. J Am Soc Nephrol. 16:3326–3338. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nasrallah R, Robertson SJ and Hébert RL:
Chronic COX inhibition reduces diabetes-induced hyperfiltration,
proteinuria and renal pathological markers in 36-week
B6-Ins2(Akita) mice. Am J Nephrol. 30:346–353. 2009. View Article : Google Scholar
|
|
34
|
Elmarakby AA, Abdelsayed R, Yao Liu J and
Mozaffari MS: Inflammatory cytokines as predictive markers for
early detection and progression of diabetic nephropathy. EPMA J.
1:117–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawai T, Masaki T, Doi S, Arakawa T,
Yokoyama Y, Doi T, Kohno N and Yorioka N: PPAR-gamma agonist
attenuates renal interstitial fibrosis and inflammation through
reduction of TGF-beta. Lab Invest. 89:47–58. 2009. View Article : Google Scholar
|
|
36
|
Ha H and Lee HB: Oxidative stress in
diabetic nephropathy: Basic and clinical information. Curr Diab
Rep. 1:282–287. 2001. View Article : Google Scholar
|
|
37
|
Forbes JM, Coughlan MT and Cooper ME:
Oxidative stress as a major culprit in kidney disease in diabetes.
Diabetes. 57:1446–1454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brownlee M: The pathobiology of diabetic
complications: A unifying mechanism. Diabetes. 54:1615–1625. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gumieniczek A: Effects of pioglitazone on
hyperglycemia-induced alterations in antioxidative system in
tissues of alloxan-treated diabetic animals. Exp Toxicol Pathol.
56:321–326. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wilkinson BL, Cramer PE, Varvel NH,
Reed-Geaghan E, Jiang Q, Szabo A, Herrup K, Lamb BT and Landreth
GE: Ibuprofen attenuates oxidative damage through NOX2 inhibition
in Alzheimer's disease. Neurobiol Aging. 33:197.e21–32. 2012.
View Article : Google Scholar
|
|
41
|
Isshiki K, Haneda M, Koya D, Maeda S,
Sugimoto T and Kikkawa R: Thiazolidinedione compounds ameliorate
glomerular dysfunction independent of their insulin-sensitizing
action in diabetic rats. Diabetes. 49:1022–1032. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Toblli JE, Ferrini MG, Cao G, Vernet D,
Angerosa M and Gonzalez-Cadavid NF: Antifibrotic effects of
pioglitazone on the kidney in a rat model of type 2 diabetes
mellitus. Nephrol Dial Transplant. 24:2384–2391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sugawara A, Uruno A, Kudo M, Matsuda K,
Yang CW and Ito S: PPARγ agonist beyond glucose lowering effect.
Korean J Intern Med. 26:19–24. 2011. View Article : Google Scholar : PubMed/NCBI
|
